Dinavisa is the body in charge of issuing the license for the production of medicinal cannabis. Currently there are 13 authorized companies. The product is used as a complementary treatment for epilepsy and multiple sclerosis.
Law 6007/18, which creates the “National Program for the study and medical and scientific research of the medicinal use of the cannabis plant and its derivatives – PROINCUMEC”, and Decree No. 9303/18, regulate the controlled production of cannabis.
In this regard, the Directorate of Sanitary Surveillance (Dinavisa) reminds that those interested in providing the product must obtain the license from said agency.
Dinavisa, in coordination with the National Anti-Drug Secretariat (SENAD) and the National Plant and Seed Quality and Health Service (SENAVE), are jointly in charge of this process.
In 2020, 13 companies obtained this license, which lasts for five years. Subsequently, renewal is required.
Cannabis oil serves as an adjuvant, that is, it can be used in conjunction with other medication against refractory epilepsy and multiple sclerosis (a disease of the nervous system that affects the brain and spinal cord).
Those who wish to access medicinal cannabis must register as patients with the named pathologies, and that the treating doctor who issues the prescription is also registered with it.
